Court accepts Hugel’s request to suspend revocation of product licenses The achievement highlights the pharmaceutical company's risk management capabilities
Translated by Ryu Ho-joung 공개 2021-12-23 08:18:46
이 기사는 2021년 12월 21일 06:54 thebell 에 표출된 기사입니다.
South Korean botox maker Hugel has obtained a court order allowing it to continue to sell its botulinum toxin products regulated by the country’s Ministry of Food and Drug Safety for now, clearing a hurdle ahead of its planned acquisition by a GS Group-led consortium.On Friday, the Seoul Administrative Court accepted the company’s request to suspend the MFDS’ decision. In November, the authority said it would revoke licenses of four botox products made by Hugel for failing to get necessary approval to supply them domestically, and ordered the company to recall and dispose of them.
Hugel immediately released a statement saying that transactions regulated by the MFDS were made to export the products, which is not subject to domestic regulations.
With Friday’s court decision, the license revocation, which took effect December 13, will be nullified until the main case filed by Hugel against the MFDS is resolved.
Hugel is set to change hands after a consortium led by South Korean conglomerate GS Group signed a deal to buy a controlling stake in the pharmaceutical company from private equity firm Bain Capital this summer.
Earlier this month, the deal received a nod from the country’s trade ministry, which concluded that the acquisition poses no concern of technology leaks. Many expect the deal to close before the deadline of January 12, 2022.
Hugel’s dealings with the MFDS highlight its strong risk management capabilities, industry watchers said. Hugel also obtained licenses for its botox products from Chinese health authorities last year to become the first such company in South Korea. This was an achievement by the company which sought to expand into global markets amid cutthroat competition among domestic botox makers.
“We are not shaken by the acquisition process and other issues and continue to focus on increasing our competitiveness,” an official at Hugel said. “We will also increase shareholder value by retiring treasury shares and paying dividends.” (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감